Cadenza Bio is dedicated to breaking the cycle of MS, leading to transformative changes in patient lives. This goal extends beyond symptom relief; they strive to halt the progression of disease and return high quality of life to patients.
Why we invested:
Cadenza Bio was founded to accelerate and support the development of a series of novel, non-steroidal, highly selective compounds targeting Estrogen Receptor â (ERâ). Its patented and patent-pending compounds have shown therapeutic efficacy in preclinical animal models of MS and Endometriosis.
Founders & Team
Founder/CEO Carol Curtis, PhD has strong expertise in company building, early-stage venture capital, managing operations and R&D, and interacting with FDA. Founder/COO Elaine Hamm, PhD has extensive experience in drug development and technology transfer and has successfully exited two portfolio companies.